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Abstract 
 PET studies allow in vivo imaging of the density of brain receptor species. The PET 
signal, however, is the sum of the fraction of radioligand that is specifically bound to the target 
receptor and the non-displaceable fraction (i.e. the non-specifically bound radioligand plus the 
free ligand in tissue). Therefore, measuring the non-displaceable fraction, which is generally 
assumed to be constant across the brain, is a necessary step to obtain regional estimates of 
the specific fractions. 
The nondisplaceable binding can be directly measured if a reference region, i.e. a 
region devoid of any specific binding, is available. Many receptors are however widely 
expressed across the brain, and a true reference region rarely available. In these cases, the 
nonspecific binding can be obtained after competitive pharmacological blockade, which is 
often contraindicated in humans. 
In this work we introduce the genomic plot for estimating the nondisplaceable fraction 
using baseline scans only. The genomic plot is a transformation of the Lassen graphical 
method in which the brain maps of mRNA transcripts of the target receptor obtained from the 
Allen Brain Atlas are used as a surrogate measure of the specific binding. Thus, the genomic 
plot allows the calculation of the specific and nondisplaceable components of radioligand 
uptake without the need of pharmacological blockade. 
We first assessed the statistical properties of the method with computer simulations. 
Then we sought ground-truth validation using human PET datasets of seven different 
neuroreceptor radioligands, where nonspecific fractions were either obtained separately using 
drug displacement or available from a true reference region. The population nondisplaceable 
fractions estimated by the genomic plot were very close to those measured by actual human 
blocking studies (mean relative difference between 2% and 7%). However, these estimates 
were valid only when mRNA expressions were predictive of protein levels (i.e. there were no 
significant post-transcriptional changes). This condition can be readily established a priori by 
assessing the correlation between PET and mRNA expression. 
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INTRODUCTION 
 
Positron emission tomography (PET) radioligands allow in vivo imaging of the 
distribution and availability of brain receptors. Amongst the criteria for a successful 
radioligand (Pike, 2009) a high level of specific binding is of prominent importance. The PET 
signal is a mixture of specific binding (i.e. the percentage of radioligand bound to the target 
receptor) and nondisplaceable uptake, which is the sum of nonspecific binding and free ligand 
in tissue (Innis et al., 2007). The ratio at equilibrium of the specifically bound radioligand to 
that of the nondisplaceable radioligand in tissue is the binding potential (𝐵𝑃𝑁𝐷) which reflects 
the affinity of the radioligand for the target and more importantly the target availability in vivo 
(Innis et al., 2007). If the nondisplaceable component is known, then the specific component, 
and hence 𝐵𝑃𝑁𝐷, can be derived from the total activity. 
The nondisplaceable binding can be directly measured if a reference region, i.e. a 
region truly devoid of the receptors under study, is available (Lammertsma et al., 1996; 
Lammertsma and Hume, 1996). The radioligand concentration in this region then becomes 
the reference for all regions, because the nondisplaceable binding is generally assumed to be 
constant in the brain (Lammertsma and Hume, 1996). Many receptors are however 
expressed across the whole human brain, and therefore a reference region is rarely available 
(Turkheimer et al., 2012). In these instances, measuring the nondisplaceable fraction requires 
an additional scan after administration of a competitive blocking agent (Lassen et al., 1995). 
This can be achieved without the complete blockade of all receptors, because the parameter 
of interest can be derived from a simple correlation using the variation of the total binding 
before and after administration of the blocking drug. This approach, generally described as 
the Lassen plot method (Cunningham et al., 2010; Lassen et al., 1995), has however two 
disadvantages: 1) blocking drugs may not be safe for human use at pharmacological doses or 
may not be available and 2) at least two separate PET scans are necessary for each subject. 
Recently, Zanotti-Fregonara et al (Zanotti-Fregonara et al., 2015) introduced a method 
to estimate the specific and nondisplaceable components of a PET radioligand for 
metabotropic glutamate receptor 1 (mGluR1), based on the correlation of the regional density 
of the mGluR1 gene transcript with PET measurements of the expressed protein. This 
analysis is a variation of the Lassen plot, which measures the linear relationship of the tracer 
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specific binding as a function of total distribution volume in brain. In Zanotti-Fregonara et al 
(Zanotti-Fregonara et al., 2015), the regional densities of the mGluR1 gene transcript in 
human brain were strongly and linearly correlated with regional densities (distribution volume, 
𝑉𝑇) of mGluR1 measured with PET. Furthermore, the extrapolated value of 𝑉𝑇 when mGluR1 
gene transcript would equal 0 (i.e., in the absence of specific binding) was a reasonably 
accurate measure of tracer nondisplaceable volume of distribution (𝑉𝑁𝐷), based on 
pharmacological blockade in a monkey. This variation of the Lassen plot, which we call the 
“genomic plot”, has the significant advantage of estimating the specific and nondisplaceable 
components of radioligand uptake without the need for pharmacological blockade.  
The purpose of this study was to assess the wider applicability of the genomic plot to 
estimate specific and nondisplaceable components of several PET targets, including six 
receptors and one enzyme. We first validated the statistical properties of the genomic plot 
with computer simulations to test its robustness against varying brain protein and mRNA 
patterns as well as varying mRNA-protein relations for different neurotransmitter systems. We 
then sought ground-truth validation using human PET datasets where estimates of the 
nondisplaceable fraction were available from blocking studies. 
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MATERIAL AND METHODS 
 
Theory 
In a brain PET study, the radioligand activity in the tissue is typically the sum of a 
specific and a nondisplaceable component (Innis et al., 2007; Lassen et al., 1995; Mintun et 
al., 1984). Given 𝑛 regional estimates, the total volume of distribution for the 𝑗th region (𝑉𝑇,𝑗) is 
given by: 
𝑉𝑇,𝑗 =  𝑉𝑆,𝑗 + 𝑉𝑁𝐷     ∀𝑗 = 1, … , 𝑛  (Eq. 1) 
where 𝑉𝑆,𝑗 is the regional specific distribution volumes for the 𝑗
th region and 𝑉𝑁𝐷 represents the 
nondisplaceable distribution volume. The implicit assumption of Eq. 1 is that 𝑉𝑁𝐷 is constant 
across all brain regions, a common and generally valid assumption in brain neuroreceptor 
experiments (Lammertsma et al., 1996; Lammertsma and Hume, 1996; Lassen et al., 1995). 
If a close relationship exists between mRNA expression and protein concentration, the 
transcriptome then reflects the in vivo distribution of the brain protein, and therefore it can be 
used as a proxy of the specific binding of the radioligand. This can be written as: 
𝑉𝑆,𝑗 =  𝛼 ∙ 𝑚𝑅𝑁𝐴𝑗 ∀𝑗 = 1, … , 𝑛 (Eq. 2) 
where 𝑚𝑅𝑁𝐴𝑗 represents the vector of mRNA measurements for a given gene in the 𝑗
th region 
and α is the scale factor between the transcript expression (either relative or absolute) and 
the tracer specific binding. Notably, the use of a constant value for α across the different brain 
regions is a strong assumption which holds only when a linear dependence exists between 
the mRNA expression and the correspondent protein density and when the occupancy by 
endogenous neurotransmitter is uniform across brain regions. When these conditions are 
met, by combining Eq. 1 and Eq. 2, the distribution volume of the radioligand becomes 
linearly related to the mRNA expression of the target as  
𝑉𝑇,𝑗 =  𝛼 ∙ 𝑚𝑅𝑁𝐴𝑗 + 𝑉𝑁𝐷         ∀𝑗 = 1, … , 𝑛 (Eq. 3) 
Following the convention introduced for the Lassen plot for PET occupancy studies (Lassen 
et al., 1995) and given the smaller noise of PET 𝑉𝑇 compared to mRNA data, we use 𝑉𝑇 as 
the independent variable, rewriting Eq. 3 as: 
𝑚𝑅𝑁𝐴𝑗 =  
1
𝛼
∙ (𝑉𝑇,𝑗 − 𝑉𝑁𝐷)     ∀𝑗 = 1, … , 𝑛 (Eq. 4) 
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The linear regression of these two variables (x = 𝑚𝑅𝑁𝐴 and y = 𝑉𝑇) generates a plot where the 
x-axis intercept is equal to the 𝑉𝑁𝐷. We named this method the genomic version of the Lassen 
plot or simply “genomic plot”.  
 
Simulated data 
Monte-Carlo simulations were performed to assess the statistical robustness of the 
genomic plot (Eq. 4) in a number of realistic stochastic conditions reflecting: 
 Variability of the specific binding 𝑉𝑆 between brain regions (i.e. variability of 𝑉𝑆 between 
ROIs) 
 Misspecification between 𝑚𝑅𝑁𝐴 and 𝑉𝑆 (i.e. variability of 𝛼 between ROIs) indicating 
lack of linearity between gene expression and measured protein levels 
 Variability of the tracer binding potential (approximated by 𝑉𝑆/𝑉𝑁𝐷) 
For the first condition, we simulated a spectrum of 5 cases corresponding to a 𝑉𝑆 variability 
ranging from 10% (homogenous 𝑉𝑆 distribution) to 50% (heterogenous 𝑉𝑆 distribution). A 
lognormal distribution was used to avoid the generation of negative 𝑉𝑆.  
For the second condition, we simulated 11 different scenarios of 𝛼 between-region variability, 
from 1% (no misspecification between mRNA and 𝑉𝑆) to 100% (complete misspecification 
between mRNA and 𝑉𝑆). The values were randomly generated by sampling a lognormal 
distribution with mean equal to 0.1 and standard deviation proportional to the variance of 𝛼. 
This range of values for 𝛼 was chosen based on the results reported by Rizzo and colleagues 
(Rizzo et al., 2014), who showed that PET 𝑉𝑇 estimates (ml/cm
3) are approximately one order 
of magnitude lower than the linearized mRNA expression (unit less) of the correspondent 
target proteins. The analysis included 3 brain PET tracers ([11C]WAY100635, [11C]CUMI101 
and [11C]DPN) with the Allen Human Brain atlas as source for the genomic information 
(http://human.brain-map.org/).   
For the last condition, three different scenarios were tested: a low-binding case (mean 𝑉𝑆 = 
0.5 𝑉𝑁𝐷), an intermediate-binding case (mean 𝑉𝑆 = 𝑉𝑁𝐷) and a high-binding case (mean 𝑉𝑆 = 2 
𝑉𝑁𝐷). Mean 𝑉𝑆 values were used as reference to generate the regional specific bindings, and 
the between-region variability was defined accordingly to the first condition. These 
representative cases were chosen to cover the typical range of binding potential for a PET 
tracer (Guo et al., 2009). 
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𝑉𝑁𝐷 was assumed constant for all simulations (𝑉𝑁𝐷 = 2 ml/cm
3), as used previously 
(Cunningham et al., 2010). Twelve ROIs were simulated for both PET and mRNA data, which 
is a typical number of regions when brain PET scan are matched with mRNA measures 
(Rizzo et al., 2014). For all conditions, 1,000 noisy simulations were generated by adding 
Gaussian distributed noise (zero mean and 5% coefficient of variation, 𝐶𝑉) to the total 
distribution volumes, independently for each simulated ROI. This procedure, as well as the 
noise level, were defined according to the literature (Cunningham et al., 2010). In total, 
165,000 simulations (5 cases of 𝑉𝑆 variability x 11 cases of genomic misspecification x 3 
levels of binding x 1,000 simulations) were computed. A summary of the settings used for the 
simulations is reported in Table 1. 
For each simulated scenario, 𝑉𝑁𝐷 was estimated using the genomic plot (Eq. 4), and 
the results compared with the correspondent simulated values. Percentage mean bias 
(%𝑏𝑖𝑎𝑠) and root mean square error (%𝑅𝑀𝑆𝐸) were used as indexes of performance: 
%𝑏𝑖𝑎𝑠 =
100
𝑁
∑
(𝑉𝑁𝐷,𝑖− 𝑉𝑁𝐷̅̅ ̅̅ ̅̅ )
𝑉𝑁𝐷̅̅ ̅̅ ̅̅
𝑁
𝑖=1   
(Eq. 5) 
%𝑅𝑀𝑆𝐸 = 100√
1
𝑁
∑ [
(𝑉𝑁𝐷,𝑖− 𝑉𝑁𝐷̅̅ ̅̅ ̅̅ )
𝑉𝑁𝐷̅̅ ̅̅ ̅̅
]
2
𝑁
𝑖=1   
(Eq. 6) 
where 𝑁 is number of simulations (𝑁=1,000), 𝑉𝑁𝐷̅̅ ̅̅ ̅ is the simulated nondisplaceable 
distribution volume and 𝑉𝑁𝐷,𝑖 is the 𝑖
th estimated nondisplaceable distribution volume. The 
squared Pearson’s correlation coefficients (𝑅2) between simulated mRNA and simulated 𝑉𝑇 
were also analysed to assess the impact of the different tested conditions on the relationship 
between these two quantities. 
 
In vivo positron emission tomography data 
To assess the applicability of the method to clinical data, we applied the genomic plot 
to the following brain PET tracers: 1) [11C]WAY100635, targeting the serotonin 5-HT1A 
receptor (Pike et al., 1996); 2) [11C]Ro15-4513 targeting the GABA 5 receptor (Lingford-
Hughes et al., 2002); 3) [11C]LY2795050 targeting the kappa opioid receptor (Zheng et al., 
2013); 4) [18F]FIMX, targeting the metabotropic glutamate receptor 1 (Xu et al., 2013); 5) 
[11C]NOP-1A targeting the nociceptin/orphanin FQ peptide receptor (Pike et al., 2011); 6) 
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[11C](R)rolipram, targeting the phosphodiesterase 4 enzyme (Fujita et al., 2005); 7) 
[11C]Raclopride, targeting the dopamine D2 receptors (Ehrin et al., 1985). 
The choice of these radioligands was driven by the availability of in vivo 𝑉𝑁𝐷 
measurements usable as the gold standard to validate the estimates obtained with the 
genomic plot (Table 2).  Both in house data and blocking studies from literature were 
considered: 
 [11C]WAY100635: Fifteen male healthy subjects (35.7 ± 10.5 years old) underwent a 
95-min dynamic PET study in an ECAT EXACT3D (Siemens/CTI, Knoxville, TN, USA) 
scanner after a bolus injection of 301± 12 MBq of [11C]WAY100635. The data were 
analysed as previously reported (Bose et al., 2011). The data were acquired at Imanet 
PET centre, London (UK). 
 [11C]Ro15-4513: Data from previously reported study (Stokes et al., 2014) of four 
healthy male subjects (41.5 ± 4.4 years old) scanned twice were considered. All 
subjects underwent 90-min dynamic scan on an ECAT HR + 962 scanner 
(CTI/Siemens, Knoxville, TN, USA) camera after injection of ~ 450 MBq of [11C]Ro15-
4513. The data were acquired at the Imanet PET centre, London (UK). 
 [11C]LY2795050: Sixteen healthy volunteers (24 to 56 years old; 8 males/ 8 females) 
underwent a 90-min dynamic PET scan on a High Resolution Research Tomograph 
(Siemens Medical Solutions, Knoxville, TN, USA) after intravenous administration of 
tracer over 1 minute by an automatic pump (injected dose: 334 ± 149 MBq). Full details 
on PET procedures, arterial data extraction and processing are reported in (Naganawa 
et al., 2014). PET data were acquired at the Yale PET centre, New Haven, Connecticut 
(USA). 
 [18F]FIMX: Twelve healthy controls (28 ± 10 years old; 4 males/8 females) underwent a 
120-min dynamic PET scan after intravenous administration of 189 ± 3.4 MBq of 
tracer. Full details on PET procedures, arterial data extraction and processing are 
reported in (Zanotti-Fregonara et al., 2015). PET data were acquired at the NIH PET 
centre, Bethesda, Maryland (USA). 
 [11C]NOP-1A: Data from previously reported study (Lohith et al., 2014) of eleven 
healthy subjects (from 22 to 42 years old; 8 males/3 females) were considered. All the 
subjects underwent 120-min dynamic scan on an Advance tomograph (GE Medical 
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Systems, Waukesha, WI) after bolus injection of 713 ± 79 MBq of [11C]NOP-1A. Full 
details on PET protocol and data and processing are reported in (Lohith et al., 2014; 
Tonietto et al., 2015). PET data were acquired at the NIH PET centre, Bethesda, 
Maryland (USA). 
 [11C](R)rolipram: Twelve healthy controls (28 ± 11 years old; 10 males/2 females) were 
included in the analysis (Zanotti-Fregonara et al., 2011). All PET images were acquired 
using an Advance tomograph (GE Medical Systems, Waukesha, WI, USA) after a 
bolus injection of 695±152 MBq of [11C](R)-rolipram The data were analysed as 
previously reported in (Rizzo et al., 2013). PET data were acquired at the NIH PET 
centre, Bethesda, Maryland (USA). 
 [11C]Raclopride: Ten healthy controls (46.7 ± 14.1 years old; 8 males/2 females) were 
acquired using a ECAT EXACT HR++ tomograph (CTI/Siemens 966; Siemens, 
Knoxville,TN) after a bolus injection of 180-186 MBq (Pavese et al., 2006). PET data 
were acquired at the Imanet PET centre, London (UK).  
For all these studies, ethical approval was granted independently by the internal ethical 
committees of the different institutes. Regional 𝑉𝑇 estimates were quantified with a nonlinear 
weighted least square estimator applied to the 2-tissue compartmental model. For 
[11C]Raclopride, the outcome parameter was 𝐵𝑃𝑁𝐷, obtained with a simplified reference tissue 
model using the cerebellum as the reference region. For each tracer, regional population 𝑉𝑇 
(or 𝐵𝑃𝑁𝐷 for [
11C]Raclopride) estimates were obtained by averaging results across subjects 
prior to genomic plot analysis (Supplementary material - Table 1-7). Notably all the datasets 
were acquired independently (experimental conditions change from study to study) and 
processed according to the goals of the clinical studies. For example, the brain segmentation 
was inconsistent between datasets, because for each case the region contouring was defined 
to best match the tracer tissue distribution. These characteristics represented the best 
conditions to test the flexibility, robustness and general applicability of the genomic plot.  
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mRNA data and Allen Human Brain atlas 
The mRNA transcription maps were downloaded from the Allen Human Brain atlas 
(ABA) (http://www.brain-map.org) (Hawrylycz et al., 2012). This dataset is derived from six 
healthy donors (42.5 ± 13.4 years old, 5 male/1 female) and contains more than 29,000 gene 
expression profiles sampled throughout the brain. On average, 617 ± 242 samples were 
collected for each donor and the brain structures are sampled proportionally to their volume. 
For two out of the six brains, samples were collected from both hemispheres. For the 
remaining four, tissue samples for microarray analysis were limited to the left hemisphere.  
Full details about the procedures for the tissue collection and processing, the 
microarray experimental design and execution, and the data quality control up to the 
integration of the data into the online resource are reported in the supplementary data of 
Hawrylycz et al (Hawrylycz et al., 2012).  
The expression profiles of the genes downloaded from ABA were: HTR1A for 
[11C]WAY100635, GABRA5 for [11C]Ro15-4513, OPRK1 for [11C]LY2795050, GRM1 for 
[18F]FIMX, OPRL1 for [11C]NOP-1A, PDE4A, PDE4B, PDE4C and PDE4D for 
[11C](R)rolipram, and DRD2 for [11C]Raclopride. For all genes and all probes, mRNA 
expression were downloaded at the highest spatial resolution possible (i.e., each value 
represented a physical tissue sample) in log2 expression intensity. A summary of the data 
used for the analysis is available in the supplementary material.  
 
mRNA data analysis 
The individual mRNA expressions, originally mapped in the native brain MRI space, 
were spatially normalised to the standard stereotaxic space (MNI/ICBM152) using the 
transformation matrices available from the ABA data portal. Additionally, the anatomical 
classifications of the sample labels were moved on the image space to obtain brain 
segmentation consistent with the sample/structure/coarse levels of resolution, as defined in 
ABA. Based on this match, the mRNA samples belonging to the same ROIs were averaged 
across different donors. The ROIs considered were: frontal, parietal, temporal and occipital 
lobes, cingulate gyrus, hippocampus, insula, striatum, globus pallidum, amygdala, thalamus, 
cerebellum and brainstem. These regions were chosen to guarantee an adequate brain 
coverage and a sufficiently large number of samples per region (>10 per region and per 
donor). 
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Most of the gene expressions included in the ABA database are measured with two or 
more probes. The presence of multiple probes for the same gene, whose expression profiles 
may be inconsistent, does not allow the use of the mean mRNA expression as representative 
of the true mean transcript expressions. Thus, it is fundamental for any type of application to 
select only the probe that best describes the real transcript profile and discard the remaining 
ones. According to (Hawrylycz et al., 2012), for each gene we selected a unique probe, 
representative of the gene expression. Among the available probes, the one with the least 
skewed distribution across donors was chosen (Figure 1).  
The processing of the mRNA data was performed with MENGA (Multimodal 
Environment for Neuroimaging and Genomic Analysis) (Rizzo et al., 2015). This software 
package allows the integration of the mRNA transcript maps from ABA with any neuroimaging 
modality and calculates the gene vs. image cross-correlation statistics. MENGA software and 
manual are available at www.fair.dei.unipd.it/software. All analyses, including genomic plot 
implementation, were performed using Matlab®2012b (The MathWorks, Inc., Natick, MA, 
USA) on a Windows 7 computer. 
 
Genomic plot analysis  
First, mRNA data were converted from log2 intensity into linear scale. This preliminary 
step is necessary to maintain a linear relationship between mRNA measures and gene 
transcript intensity. The values were then linearly regressed with the population 𝑉𝑇 values 
from the corresponding PET tracer to determine whether the relative gene transcript was 
proportional to 𝑉𝑇. The squared Pearson’s correlation coefficient (R
2) was used to quantify the 
linear correlation. The 𝑉𝑁𝐷 values estimated by the genomic plot were then compared with the 
measured 𝑉𝑁𝐷 values obtained from the blocking studies available in the literature from 
human or nonhuman primates. For human data, the estimated 𝑉𝑁𝐷 values were directly 
compared to the measured ones. For primate data, interspecies differences were accounted 
for by correcting 𝑉𝑁𝐷 measurements for the tracer plasma free fractions of the two species 
(𝑓𝑝
ℎ𝑢𝑚𝑎𝑛𝑠 for humans and 𝑓𝑝
𝑚𝑜𝑛𝑘𝑒𝑦𝑠
  for monkeys, respectively). This resulted in: 
𝑉𝑁𝐷
ℎ𝑢𝑚𝑎𝑛𝑠 =  𝑉𝑁𝐷
𝑚𝑜𝑛𝑘𝑒𝑦𝑠  ∙  
𝑓𝑝
ℎ𝑢𝑚𝑎𝑛𝑠
𝑓𝑝
𝑚𝑜𝑛𝑘𝑒𝑦𝑠  
(Eq. 7) 
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where 𝑉𝑁𝐷
𝑚𝑜𝑛𝑘𝑒𝑦𝑠
 is the nondisplaceable distribution volume measured in blocking 
studies in nonhuman primate and 𝑉𝑁𝐷
ℎ𝑢𝑚𝑎𝑛𝑠 is its equivalent in humans. Equation 7 implicitly 
assumes that the free fraction of ligand in the nondisplaceable tissue compartment (fND) is 
unchanged between species. The procedure was implemented consistently with the approach 
presented by Zanotti-Fregonara et al (Zanotti-Fregonara et al., 2015). 
[11C]Raclopride is a particular case. Since this tracer targets dopamine D2 receptors, a 
true reference region (i.e. the cerebellum) is available. Therefore, [11C]Raclopride can be 
quantified with 𝐵𝑃𝑁𝐷, without any peripheral blood measurement. If the assumption used for 
VT (i.e. mRNA predicts the protein density in vivo) holds for [
11C]Raclopride, then the intercept 
of the regression line should cross the origin of the axes. 
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RESULTS  
 
Simulated data 
Figure 2 shows some representative genomic plots applied to different cases of 
simulated data with 𝑉𝑁𝐷= 2 ml/cm
3 and 𝐵𝑃𝑁𝐷 =1 (intermediate-binding case). When the 
genomic misspecification (i.e. the misspecification between mRNA and 𝑉𝑆) is minimal (𝐶𝑉 𝛼 = 
1%, Figure 2A and C), mRNA vs. 𝑉𝑇 correlation is very high (R
2>0.99) and the bias is <1%. 
On the contrary, when misspecification is maximal (𝐶𝑉 𝛼 = 100%), the correlation between 
transcript and 𝑉𝑇 decreases (R
2 = 0.40 and R2 = 0.48, Figure 2B and D respectively) and this 
affects the precision and accuracy of 𝑉𝑁𝐷 quantification. Notably, when the 𝑉𝑆 variability 
between regions is maximal (𝐶𝑉 𝑉𝑆 = 50%, Figure 2C and D), the performance is better than 
when the specific binding is uniform across regions (𝐶𝑉 𝑉𝑆 = 10%, Figure 2A and B 
respectively). 
These results are confirmed by the overall method performance across the different 
simulated scenarios (Figure 3). The correlation matrix (Figure 3A) follows a bimodal 
behaviour: the correlation values are high (R2>0.8) when the level of genomic misspecification 
is low (𝐶𝑉 𝛼 < 20%); with higher values for higher 𝑉𝑆 variability. On the contrary, the lowest 
correlation values (R2 < 0.2) are found when genomic misspecification is high (𝐶𝑉 𝛼 > 30%). 
Similar to the previous cases, the higher the 𝑉𝑆 variability between regions the better the 
mRNA vs. 𝑉𝑇 correlation. These results are independent from 𝑉𝑁𝐷 and from the simulated 
level of specific binding.  
In agreement with the correlation matrix results, %𝑏𝑖𝑎𝑠 is also similarly dependent on 
genomic misspecification and 𝑉𝑆 variability (Figure 3B-D). The best performance is found for 
the lowest misspecification (𝐶𝑉 𝛼 = 1%) and the highest 𝑉𝑆 variability (𝐶𝑉 𝑉𝑆 = 50%), and the 
worst results are obtained in the opposite case (𝐶𝑉 𝛼 = 100%, 𝐶𝑉 𝑉𝑆 = 10%). Differently from 
the correlation analysis, the level of specific binding of the radioligand affects the overall 
performance: the lower the 𝑉𝑆/𝑉𝑁𝐷 ratio, the lower the bias. The %𝑏𝑖𝑎𝑠 average (mean±SD) is 
70%±636% (median -2.4%) for high-binding case, 17%±54% (median -1.5%) for 
intermediate-binding case, and -13%±70% (median -0.6%) for low-binding case. Consistently, 
%𝑅𝑀𝑆𝐸 medians range from 82% in the high-binding case to 10% in the low-binding case. 
The variability of %𝑏𝑖𝑎𝑠 highlights the high sensitivity of genomic plot performances to the 
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ability of mRNA to correctly predict the in vivo protein density: the reliability of the method is 
inversely proportional to the genomic misspecification. 
This is important piece of information, as the correlation between mRNA and 𝑉𝑇 can be 
used to predict the performance, here intended in terms of bias, of the genomic plot. Defining 
95% of confidence interval of the estimates, simulation results suggested that the genomic 
plot can yield an absolute %𝑏𝑖𝑎𝑠<5% when R2>0.4 for low-binding scenario, R2>0.6 for 
intermediate-binding scenario and R2>0.85 for the high-binding scenario. Similarly, an 
absolute %𝑏𝑖𝑎𝑠< 10% could be obtained with a correlation R2>0.25 for low-binding scenario, 
R2>0.4 for intermediate-binding scenario and R2>0.75 for the high-binding scenario. Notably, 
these thresholds are valid only within the particular settings used for the simulations and need 
to be further validated by analysing actual measured data. 
 
 
Performances in vivo measured datasets 
Table 2 reports a summary of the genomic results in the measured PET datasets. A 
variable degree of correlation between mRNA and 𝑉𝑇 was found among the different tracers. 
The highest correlation was found for [18F]FIMX, [11C]WAY100635 and [11C]Ro15-4513 (R2 > 
0.80) while a low correlation was obtained for [11C]LY2795050 (R2 = 0.25). For [11C]NOP1A 
and [11C](R)rolipram, no correlation was found (R2 < 0.1). Notably, the different number and 
type of regions used for the comparison did not appear to play a role in the correlation 
between PET imaging and mRNA expression. For all tracers, 9 to 12 ROIs were analysed 
(Table 2). 
Similarly to the results obtained in simulated data, the best consistency between 
estimated and measured 𝑉𝑁𝐷 values was obtained for the tracers in which genomic plot 
showed the highest correlation between PET and mRNA expression (Figure 4). Specifically 
these were [11C]WAY100635 (estimated 𝑉𝑁𝐷 = 0.30 ml/cm
3 – measured 𝑉𝑁𝐷 0.28±0.43 
ml/cm3) and [11C]Ro15-4513 (estimated 𝑉𝑁𝐷 = 2.14 ml/cm
3 – measured 𝑉𝑁𝐷 2.13±0.80 
ml/cm3), followed by [18F]FIMX (estimated 𝑉𝑁𝐷/𝑓𝑝 = 138 ml/cm
3 – measured 𝑉𝑁𝐷/𝑓𝑝 170 
ml/cm3).  
As predicted by the lack of any correlation between mRNA and PET, inaccurate results 
were obtained for [11C]LY2795050 (estimated 𝑉𝑁𝐷 = 0.26 ml/cm
3 – measured 𝑉𝑁𝐷 1.69±0.13 
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ml/cm3), while for [11C]NOP1A and [11C](R)rolipram non-physiological estimates were 
returned by the genomic graphical analysis (Figure 5).  
Finally, as predicted from theoretical considerations, the regression line between 
mRNA data of D2 receptors and 𝐵𝑃𝑁𝐷 values of [
11C]Raclopride crossed the origin of the axes 
(Figure 6). 
 
 Impact of probe selection 
 Since for all genes multiple probes exists on mRNA microarrays we further 
investigated the application of the genomic plot to [11C]WAY100635, [11C]Ro15-4513 and 
[11C]LY2795050 (i.e. the tracers with human blocking study available) using  secondary 
probes that were not originally selected as representative; the result is reported in Figure 7. 
For each tracer most of the probes presented similar correlations with PET tracer activity and 
led to consistent 𝑉𝑁𝐷 estimates. Notably, these probes were also highly cross-correlated 
among each other (mean R2 = 0.92 for [11C]WAY100635, 0.95 for [11C]Ro15-4513 and  0.94 
for [11C]LY2795050). Nevertheless, some probes did not correlate with the nominated probes 
nor with in vivo imaging (R2 < 0.01) and did not yield physiological 𝑉𝑁𝐷 estimates. These 
probes were CUST_15880_PI416261804 for [11C]WAY100635 and CUST_495_PI416408490 
for [11C]LY2795050. Notably, both probes were characterized by a high number of low-
expressed samples hence indicating that only probes with high affinity and abundant binding 
to the specific mRNA species should be selected for further processing. 
These results were confirmed when the analysis was extended to the tracers for which 
only nonhuman blocking studies were available. For both [11C]NOP1A and [11C](R)rolipram, 
the use of secondary probes confirmed a non-significant correlation between mRNA and PET 
𝑉𝑇 (R
2<0.1) and yielded negative 𝑉𝑁𝐷 estimates. Also for [
18F]FIMX, the application of the 
genomic plot using secondary mRNA probes led to not physiological results. Notably these 
secondary probes were characterized by higher between-donor variability than the primary 
one. High correlation was found between primary and secondary probes for the DRD2 gene 
(R2=0.85±0.10), resulting in no significant changes in the genomic plot performance. 
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DISCUSSION 
In this work, we presented an original approach for estimating the specific and 
nondisplaceable fractions of brain PET radioligands without using pharmacologically blocked 
studies. 
 The method derives the non-specific volume of distribution 𝑉𝑁𝐷 from the linear 
relationship between the relative regional density of the mRNA transcripts of the target 
receptor (considered as proxy of the tracer specific binding) and the regional volumes of 
distribution of the radioligand at baseline. 
The proposed approach can be considered as a genomic variant of the Lassen plot 
(Lassen et al., 1995), and therefore was named genomic plot. It is worth noting that several 
versions of the Lassen plot have been previously introduced, where non-specific fractions 
were obtained either in the absence of a drug free scan (multiple drug levels but no 
baseline)(Cunningham et al., 2010), with partial blocking (Owen et al., 2014), or in the 
presence of varying affinities across subjects due to genetic polymorphisms (Guo et al., 
2014). With the genomic plot, we have introduced the use of transcript densities as a proxy 
for protein density and the specific volume 𝑉𝑆.  
 
Method applicability 
Because the Allen Human Brain atlas contains the transcript maps of 29,179 human 
brain proteins, the genomic plot potentially has potentially wide applicability. In practice, a 
number of conditions affect the performance of the method. One critical assumption is related 
to the ability of gene transcript to predict protein density. At least three factors may potentially 
explain the poor correlations reported in the literature between mRNA and protein 
concentrations, and these may not be mutually exclusive (Maier et al., 2009). First, post-
transcriptional mechanisms (e.g. transcriptional and post-transcriptional splicing, translational 
modifications and protein complex formations) influence the degree to which mRNA 
expression translates into protein expression; second, proteins may differ substantially in their 
in vivo half-lives; third, technologies may not be perfectly accurate in measuring either mRNA 
or protein content. In addition, limitations in postmortem tissue availability and quality may 
further degrade the quality of genomic maps and their predictive level. In general, the strength 
of correlation between mRNA and in vivo protein density varies among genes depending on 
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their function: it is stronger for genes related to cellular structure and lower or negligible for 
those related to cell development and the regulation of cellular function (Guo et al., 2008; 
Rizzo et al., 2014).  
Other implicit assumptions for the applicability of the genomic plot regard the existence 
of a perfect correspondence between genomic and imaging samples a uniform occupancy of 
the endogenous neurotransmitter across the regions. For the first condition we developed a 
method that scrupulously couples brain imaging with genomic data. By taking advantage of 
the detailed spatial information of the ABA database, we were able to generate a univocal 
correspondence between imaging and mRNA samples. This procedure is implemented in the 
MENGA software. The heterogeneity of endogenous binding, instead, is more difficult to 
control and may potentially limit the applicability of the genomic plot. It is important to highlight 
that the characteristics of the PET population must match with those of the mRNA donors. 
Since the presence of neurological or psychiatric diseases can unevenly affect the tracer 
uptake across brain regions, we recommend the use only with healthy controls. 
Nevertheless, for all tested cases, both in simulations and measured data, we found 
that when mRNA expressions are well correlated to the PET signal at baseline the genomic 
plot yields accurate and precise estimates of the tracer non-specific fraction. On the contrary, 
when this condition is not met, the method was ineffective and its bias directly followed the 
misspecification between mRNA and PET. Thus, the correlation between mRNA and 𝑉𝑇 can 
be verified beforehand to predict whether the genomic plot will work for a given radioligand. 
Our simulations and analyses of clinical data found a mean bias lower than 10% when the 
correlation between mRNA and 𝑉𝑇 (R
2) was greater than 0.75. This threshold can be relaxed 
with low or intermediate-binding tracers (𝐵𝑃𝑁𝐷 ≤1), i.e. when the 𝑉𝑇 carries more information 
on the 𝑉𝑁𝐷 than 𝑉𝑆. Similarly, both simulations and clinical analyses showed that a higher 
correlation can be obtained more easily when the specific binding is variable between regions 
rather than uniformly distributed across the brain.  
 
Method performances 
The results obtained by the genomic plot on measured PET datasets in terms of 
accuracy matched quite well the a priori expectation for the different systems. 𝑉𝑁𝐷 
quantification was unreliable for [11C]LY2795050, [11C]NOP1A and [11C](R)rolipram. The first 
two are radioligands for the opioid system. For this system, well-known post-translational 
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events control the production of mRNA variants and differentially modify proteins from each 
opioid receptor gene (Wei et al., 2004). By contrast, the target of [11C](R)rolipram is an 
intracellular enzyme, PDE4, which is part of the cAMP cascade. The bioactivity of this 
enzyme, and its affinity for [11C](R)rolipram, is modulated through phosphorylation (Fujita et 
al., 2005). In particular, phosphorylation is lost in non-living tissues and therefore the 
relationship between [11C](R)rolipram binding in vivo and mRNA expression post-mortem may 
not be preserved. 
In contrast, serotoninergic receptors, with the exception of the 5-HT2C sub-type (Burns 
et al., 1997), are not known to undergo post-translational modifications, which explains the 
precision of the genomic plot for [11C]WAY100635. Also, the analysis of [11C]Ro15-4513 and 
[18F]FIMX yielded 𝑉𝑁𝐷 estimates in agreement with those obtained by occupancy studies in 
human and nonhuman primate respectively. Notably, it is unknown whether the mRNA 
expressions of GABA 5 and mGlu1 receptors can predict in vivo protein distribution 
(Berthele et al., 1999; Wisden et al., 1992), although this is likely, given the high correlation 
between mRNA and PET uptake (R2>0.9). Moreover, both GABA 5 and mGluR1 are 
widespread across brain and present higher expression values in some regions 
(hippocampus and forebrain for GABA 5, cerebellum for mGluR1). This uneven distribution 
of PET uptake represents the ideal condition for using the genomic plot.  
Finally, the genomic plot yielded reliable results also for [11C]Raclopride data. 
[11C]Raclopride, a dopamine D2 radioligand, is commonly quantified using a reference region, 
usually the cerebellum. The outcome parameter, 𝐵𝑃𝑁𝐷, does not require blood sampling or 
correction for plasma free fraction, since both the input function and the free fraction are 
supposed to be equal across the different brain regions. As predicted from theoretical 
considerations, the intercept of the regression between mRNA and 𝐵𝑃𝑁𝐷 values crossed the 
origin of the axes. 
The validation of the method was limited by the blocking studies available in our 
centres and in the published literature. It should be noted that, compared to other studies in 
which only a single tracer was used for validation (e.g. Cunningham et al., 2010 or 
Turkheimer et al., 2007), the applicability of the methodology presented in this study was 
tested on multiple tracers directed to different brain systems.  In particular, the use of 
nonhuman primate data can be justified under several aspects: 1) Nonhuman primate data 
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have been used to validate the Lassen plot (e.g. Cunningham et al., 2010); 2) Nonhuman 
primates are often used when blocking studies are not feasible in humans; 3) The application 
of the genomic plot to nonhuman data allows assessing the method in suboptimal conditions. 
 
Single subject applicability 
Differently from the other Lassen plot methods, the genomic plot has been tested on 
population averages rather than on individual data. As a result, the method yields only 
population 𝑉𝑁𝐷 estimates instead of single subject results. There are several reasons behind 
this choice, mainly related to the mRNA data characteristics. First, genomic maps and PET 
images cannot be derived from the same subject but belong to different populations. Second, 
𝑉𝑁𝐷 values are generally quite similar among subjects of the same species, and population 
values are often used as measure of tracer non-specific binding performance. 
Indeed, when we tried to match single PET subjects to the population mRNA, we 
observed significant between-subject variability (Supplementary Material – Figure 1) and 
percentage bias (mean±SD = 10%±5%; range 1%:18%) (Supplementary Material – Figure 2). 
For this particular analysis, we used [11C]WAY100635 because this tracer showed the best 
correlation with genomic expression and [11C]Raclopride, for which the individual reference 
region was used as reference for the non-displaceable binding of each subject. Based on 
these results, we recommend the use of the genomic plot only at the population level. 
 
Methodological Considerations 
The genomic plot is based on a standard linear regression. Despite the simplicity of the 
methodology it is important to take into account the impact of axes convention or the type of 
estimator. Both 𝑉𝑇 and mRNA values are noisy, and when used as independent variables the 
noise can bias the final estimates. In our analyses, inverting the axes (mRNA on x-axis and 𝑉𝑇 
on y-axis – corresponding to Eq. 3) led to significantly higher bias and variability for all the 
tested scenarios (data not shown). This is explained by the fact that regional population 𝑉𝑇 
values are generally less noisy than the correspondent mRNA data and therefore preferable 
as independent variables. Nevertheless, both the noise level and the variability of 
measurements can change depending on the radioligand and the system under study. In this 
case, alternative estimation methods, which take into account noise on both axes (Bekker, 
1986), may be considered (e.g. likelihood estimation (Ogden, 2003) or orthogonal regression 
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(Varga and Szabo, 2002)). These methods, similarly to weighted estimation approaches, 
necessitate assumptions about the noise distributions of the measurements. Realistic 
assumptions are difficult to make: both 𝑉𝑇 and mRNA are used as population averages in 
which it is necessary to distinguish the true inter-subject biological variability to random noise. 
Further investigations to solve this issue are necessary, although our analysis with the 
standard regression showed good performance, similarly to all the other versions of the 
Lassen plot (Cunningham et al., 2010; Lassen et al., 1995).  
 
Probe selection 
In the Allen Human Brain database, only 30% of the genes are univocally represented 
by a single probe. More than 50% are described by two probes, and 19% by three or more. 
For the most studied proteins the number of available probes can be greater than 30 (see for 
example monoamine oxidase A (Zanotti-Fregonara et al., 2014). The availability of multiple 
probes is not necessarily an advantage as the different specificity and sensitivity of the probes 
to the target can lead to inconsistent expression profiles across the brain for the same gene. 
Therefore, probe selection becomes a critical processing step as it heavily impacts on the 
final results. Notably, due to the between-probe discrepancy, probe averaging does not 
represent a viable strategy because the mean expression can be more inaccurate than the 
single probe profiles.  
In this work we implemented a data-driven method for probe selection. To ensure that 
the method is generally applicable, no biological assumptions were used. The approach used 
between-donor consistency (e.g. correlation of probes expression across subjects) and 
abundancy of probe binding to select the most representative expression profile for a given 
gene. Notably the comparison between mRNA and imaging can be exploited in the opposite 
direction, i.e. by using the PET to test mRNA expression measurements. Large numbers of 
postmortem human studies use gene transcript density as a surrogate for protein levels. 
When a PET radioligand exists for a protein target, the genomic plot can validate that 
assumption and help selecting which of the multiple transcripts should be used as a surrogate 
measure.  
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CONCLUSION 
The genomic variant of the Lassen plot, or genomic plot, allows the estimation of a 
PET radioligand nondisplaceable fraction in the absence of reference region and without 
requiring target-competition studies. The method has general applicability to any 
neuroreceptor PET tracer, because it relies on mRNA brain maps of the whole human 
genome. Nevertheless, its precision is dependent on the ability of mRNA expression to 
predict protein density. Therefore, the consistency between mRNA and PET should be 
verified a priori. 
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TABLE 1 – Simulation variables 
Nondisplaceable  binding (𝑉𝑁𝐷) 
Mean (ml/cm
3
) 2 
Type of distribution Constant  
Specific binding (𝑉𝑆) 
Mean (ml/cm
3
) 1 (low-binding case), 2 (intermediate-binding case) and  
4 (high-binding case) 
𝐶𝑉 (𝜎/mean)  10%, 20%, 30%, 40% and 50% 
Type of distribution Lognormal 
Scale factor between mRNA and Vs (𝛼) 
Mean (ml/cm
3
) 0.1 
𝐶𝑉 (𝜎/mean) 1%, 2%, 3%, 4%, 5%,10%, 20%, 30%, 40%, 50% and 100% 
Type of distribution Lognormal 
Other variables 
Number of ROIs per simulated dataset  12 
Number of simulations per scenario 1,000 
 
𝐶𝑉: coefficient of variation; 𝜎: standard deviation 
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TABLE 2 – Performance of the genomic plot in the measured PET datasets 
Tracer Target mRNA vs. 𝑽𝑻 
correlation (R
2
) 
N. ROIs  Estimated 𝑽𝑵𝑫 
(ml/cm
3
) 
Expected 𝑽𝑵𝑫 
(ml/cm
3
) 
Ref(s) 
[
11
C]WAY100635 serotonin 5-HT1A 
receptor 
0.91 12
a
 0.30±0.02 0.28±0.43
†
 (Cunningham 
et al., 2010) 
[
11
C]Ro15-4513 GABA 5 receptor 0.80 10
b
 2.14±0.24 2.13±0.80
†
 
 
(Myers et al., 
2015) 
[
11
C]LY2795050 kappa opioid receptor 0.25 11
c
 0.26±3.43 1.69±0.13
†
 (Naganawa et 
al., 2014) 
[
18
F]FIMX  metabotropic 
glutamate receptor 1 
0.99 11
d
 0.47±0.02  
(𝑉𝑁𝐷/𝑓𝑝
ℎ𝑢𝑚𝑎𝑛𝑠 = 
138) 
0.58±0.03
‡
 
(𝑉𝑁𝐷/𝑓𝑝
𝑚𝑜𝑛𝑘𝑒𝑦𝑠
 
= 170) 
(Zanotti-
Fregonara et 
al., 2015) 
[
11
C]NOP-1A nociceptin/orphanin 
FQ peptide receptor 
<0.01 9
e
 n.a. 7.08 ± 0.47
‼ 
  
(Kimura et al., 
2011) 
[
11
C](R)rolipram phosphodiesterase 4 
enzyme 
<0.01 12
a
 n.a. 0.60 ± 0.12
‡ 
(𝑉𝑁𝐷/𝑓𝑝
𝑚𝑜𝑛𝑘𝑒𝑦𝑠
 
= 9.63) 
(Unpublished 
data from the 
NIH) 
𝑉𝑇: total distribution volume; 𝑉𝑁𝐷: nondisplaceable distribution volume 𝑓𝑝: free plasma fraction; n.a.: not available. 
 
REGION SEGMENTATIONS: 
a
 Frontal lobe, Parietal lobe, Temporal lobe, Occipital lobe, Cingulate gyrus,  Insula, Striatum, Globus pallidum, Basal forebrain,  Amygdala, 
Thalamus, Cerebellum 
b
 Frontal lobe, Parietal lobe, Temporal lobe, Occipital lobe, Cingulate gyrus,  Hippocampus, Insula, Striatum,  Thalamus, Cerebellum 
C
 Frontal lobe, Temporal lobe, Occipital lobe, Cingulate gyrus, Hippocampus, Insula, Striatum, Globus pallidum, Amygdala, Thalamus, 
Cerebellum  
d
 Frontal lobe, Parietal lobe, Temporal lobe, Occipital lobe, Cingulate gyrus, Hippocampus, Insula, Striatum, Amygdala, Thalamus, 
Cerebellum  
e
 Frontal lobe, Parietal lobe, Temporal lobe, Occipital lobe, Cingulate gyrus, Striatum, Thalamus, Cerebellum, Brainstem 
 
TYPE OF BLOCKING 
† 
Blocking study in humans; 
‡
Blocking study in monkeys corrected for 𝑓𝑝 interspecies differences;
 ‼
 Blocking study in monkeys NOT 
corrected for 𝑓𝑝 interspecies differences   
 24 
 
FIGURES 
Figure 1 – Example of probe selection for the 5TH1A receptor. A) Probe expression 
profiles as derived from the Allen Human Brain atlas (http://human.brain-map.org/) searching 
for HTR1A gene (setting: course level, log2 intensity, 6 donors). B) Normalised mRNA 
expression distributions (z-score) for the 3 probes of the HTR1A gene. For each probe the 
data from all the donors are reported. The probe of choice was CUST_575_PI417557136. 
The selection was done by comparing the normalised distributions and by selecting the one 
with the maximum correspondence to the highest z-score value (For further information 
please refer to MENGA’s software manual - www.fair.dei.unipd.it/software).  
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Figure 2 – Examples of simulated data. Representative genomic plots in different simulated 
conditions: 10% of 𝑉𝑆 variability and 1% of genomic misspecification (A); 10% of 𝑉𝑆 variability 
and 100% of genomic misspecification (B); 50% of 𝑉𝑆 variability and 1% of genomic 
misspecification (C); 50% of 𝑉𝑆 variability and 100% of genomic misspecification (D). In all the 
cases 𝑉𝑁𝐷 and mean 𝑉𝑆 are equal to 2 ml/cm
3 (corresponding to intermediate-binding 
simulated scenario). 
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Figure 3 – Performance of the genomic plot in simulated data. A) 𝑉𝑇 vs. mRNA mean 
correlation (R2) as function of 𝑉𝑆 variability and genomic misspecification. B-D) Absolute 
%𝑏𝑖𝑎𝑠 as function of 𝑉𝑆 variabilty and genomic misspecification in low-binding scenario (𝐵𝑃𝑁𝐷 
= 0.5), intermediate-binding scenario (𝐵𝑃𝑁𝐷 = 1) and high-binding scenario (𝐵𝑃𝑁𝐷 = 2) 
respectively. 
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Figure 4 – Genomic plot in PET measured data: successful cases. A) [11C]WAY100635 
(15 subjects), B) [11C]Ro15-4513 (4 subjects) and C) [18F]FIMX (12 subjects). Data points (●) 
indicate regional population values. Both 𝑉𝑇 (x-axis) and mRNA (y-axis) standard errors are 
reported. Red lines refer to genomic plot regressions. Black dashed lines refer to the data 
regression with x-intercepts forced to the reference 𝑉𝑁𝐷  values, i.e. the 𝑉𝑁𝐷 values as derived 
from independent blocking studies.  Please note that with [18F]FIMX the correlation is driven 
by a very high uptake region (i.e. cerebellum). When this is removed from the plot, the 
correlation is still significant (R2 = 0.65). 
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Figure 5 – Genomic plot in PET measured data: unsuccessful cases. A) [11C]LY2795050 
(16 subjects), B) [11C]NOP1A (11 subjects) and C) [11C](R)rolipram (12 subjects). Data points 
(●) indicate regional population values. Both 𝑉𝑇 (x-axis) and mRNA (y-axis) standard errors 
are reported. Red lines refer to genomic plot regressions. Black dashed lines refer to the data 
regression with x-intercepts forced to the reference 𝑉𝑁𝐷  values, i.e. the 𝑉𝑁𝐷 values as derived 
from independent blocking studies. 
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Figure 6 – Genomic plot application to [11C]Raclopride brain PET data. The figure shows 
the regression between mRNA D2 receptor expressions and [11C]Raclopride 𝐵𝑃𝑁𝐷 estimates 
as computed with the simplified reference tissue model, using the cerebellum as reference 
region (10 subjects). Analyses were performed in the following region of interest: frontal lobe, 
parietal lobe, temporal lobe, occipital lobe, cingulate gyrus, hippocampus, insula, striatum and 
thalamus (A). When the striatum is removed the correlation dropped and with it the 
performance of the method (B). Both 𝐵𝑃𝑁𝐷 (x-axis) and mRNA (y-axis) standard errors are 
reported. Red lines refer to genomic plot regressions. Black dashed lines refer to the data 
regression with x-intercepts forced to the origin. 
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Figure 7 – Impact of probe selection on [11C]WAY100635 (A), [11C]Ro15-4513 (B) and 
[11C]LY2795050 (C) analysis. Reference 𝑉𝑁𝐷 estimates as obtained from blocking studies 
(red bars) are compared with those obtained from genomic plot applications (blue bars). For 
each tracer all the probes available from the Allen Human Brain database were tested. Dark 
blue bars refer to 𝑉𝑁𝐷 estimates as obtained from the probes selected a priori from the 
database. Light blue bars refer to 𝑉𝑁𝐷 estimates derived by the probes discarded from the 
initial selection. For each probe the 𝑉𝑁𝐷 standard error and the correlation with PET tracer 
uptake are also reported (squared Pearson’s correlation coefficient, R2). Probes are sorted in 
descending order based on their correlation values with PET. 
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Supplementary Table 1 – [11C]WAY100635 data 
ROIs 
𝑽𝑻 
(ml/cm3) 
mRNA 
(unitless) 
Frontal lobe 1.50 ± 0.85 53.9 ± 8.7 
Parietal lobe 1.42 ± 0.77 43.4 ± 12.4 
Temporal lobe 1.88 ± 0.85 78.7 ± 7.2 
Occipital lobe 1.21 ± 0.58 36.5 ± 53.3 
Cingulate gyrus 1.88 ± 0.77 57.6 ± 3.0 
Hippocampus 1.81 ± 1.05 n.a. ± n.a. 
Insula 1.95 ± 1.12 83.6 ± 9.0 
Striatum 0.59 ± 0.39 5.6 ± 0.6 
Globus pallidus 0.48 ± 0.46 10.5 ± 3.3 
Basal forebrain 0.63 ± 0.27 28.8 ± 35.2 
Claustrum n.a. ± n.a n.a. ± n.a. 
Amygdala 1.45 ± 0.77 45.2 ± 66.4 
Thalamus 0.58 ± 0.35 16.0 ± 3.4 
Cerebellum 0.53 ± 0.58 3.8 ± 0.2 
Brainstem 0.52 ± 0.39 n.a. ± n.a. 
 
Distribution volume estimates (𝑉𝑇) refer to a population of 15 healthy subjects (Bose et al., 2011). Genomic data 
(mRNA) are derived from the Allen human brain atlas (query: HTR1A). For each region the average values and the 
standard deviations across subjects are reported. 
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Supplementary Table 2 – [11C]Ro15-4513 data 
ROIs 
𝑽𝑻 
(ml/cm3) 
mRNA 
(unitless) 
Frontal lobe 4.07 ± 0.44 285 ± 71 
Parietal lobe 3.70 ± 0.51 208 ± 57 
Temporal lobe 4.96 ± 0.53 317 ± 81 
Occipital lobe 3.90 ± 0.48 165 ± 51 
Cingulate gyrus 5.89 ± 0.52 349 ± 104 
Hippocampus 7.82 ± 0.85 852 ± 76 
Insula 5.11 ± 0.54 436 ± 182 
Striatum 4.18 ± 0.51 293 ± 95 
Globus pallidus n.a. ± n.a. 27 ± 49 
Basal forebrain n.a. ± n.a. 204 ± 9 
Claustrum n.a. ± n.a. 818 ± 84 
Amygdala 7.61 ± 0.87 n.a. ± n.a. 
Thalamus 2.73 ± 0.2 148 ± 36 
Cerebellum n.a. ± n.a. 7 ± 30 
Brainstem n.a. ± n.a. n.a. ± n.a. 
 
Distribution volume estimates (𝑉𝑇) refer to a population of 4 healthy subjects (Stokes et al., 2014). Genomic data 
(mRNA) are derived from the Allen human brain atlas (query: GABRA5). For each region the average values and the 
standard deviations across subjects are reported. 
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Supplementary Table 3 – [11C]LY2795050 data 
ROIs 
𝑽𝑻 
(ml/cm3) 
mRNA 
(unitless) 
Frontal lobe 2.66 ± 0.29 16.8 ± 3.1 
Parietal lobe n.a. ± n.a. 13.7 ± 2.7 
Temporal lobe 2.74 ± 0.30 16.9 ± 1.9 
Occipital lobe 2.58 ± 0.26 11.5 ± 2.5 
Cingulate gyrus 2.74 ± 0.38 18.8 ± 3.1 
Hippocampus 2.31 ± 0.28 16.2 ± 5.5 
Insula 3.41 ± 0.34 24.4 ± 5.2 
Striatum 2.60 ± 0.36 22.9 ± 3.9 
Globus pallidus 3.11 ± 0.37 6.1 ± 2.0 
Basal forebrain n.a. ± n.a. 20.6 ± 8.0 
Claustrum n.a. ± n.a. 76.6 ± 19.0 
Amygdala 3.95 ± 0.51 35.8 ± 15.3 
Thalamus 2.14 ± 0.21 27.8 ± 10.2 
Cerebellum 1.96 ± 0.18 8.8 ± 4.0 
Brainstem n.a. ± n.a. 17.8 ± 5.0 
 
Distribution volume estimates (𝑉𝑇) refer to a population of 16 healthy subjects (Naganawa et al., 2014). Genomic 
data (mRNA) are derived from the Allen human brain atlas (query: OPRK1). For each region the average values and 
the standard deviations across subjects are reported. 
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Supplementary Table 4 – [11C]FIMX data 
ROIs 
𝑽𝑻 
(ml/cm3) 
mRNA 
(unitless) 
Frontal lobe 2.4 ± 0.31 22.3 ± 3.1 
Parietal lobe 2.3 ± 0.28 21.4 ± 3.3 
Temporal lobe 3.1 ± 0.37 28.3 ± 3.2 
Occipital lobe 2.7 ± 0.46 19.3 ± 3.4 
Cingulate gyrus 2.8 ± 0.41 23.5 ± 3.5 
Hippocampus 2.9 ± 0.39 32.6 ± 3.7 
Insula 3.0 ± 0.41 29.1 ± 4.8 
Striatum 1.8 ± 0.21 17.4 ± 3.4 
Globus pallidus n.a. ± n.a. 22.0 ± 5.3 
Basal forebrain n.a. ± n.a. 21.5 ± 3.5 
Claustrum n.a. ± n.a. 17.9 ± 9.1 
Amygdala 2.7 ± 0.37 20.4 ± 4.7 
Thalamus 3.3 ± 0.50 34.3 ± 5.2 
Cerebellum 13.4 ± 1.90 144.1 ± 24.0 
Brainstem n.a. ± n.a. 14.2 ± 2.4 
 
Distribution volume estimates (𝑉𝑇) refer to a population of 12 healthy subjects (Zanotti-Fregonara et al., 2015). 
Genomic data (mRNA) are derived from the Allen human brain atlas (query: GMR1).  For each region the average 
values and the standard deviations across subjects are reported. 
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Supplementary Table 5 – [11C]NOP-1A data 
ROIs 
𝑽𝑻 
(ml/cm3) 
mRNA 
(unitless) 
Frontal lobe 9.0 ± 0.83 32.4 ± 3.3 
Parietal lobe 9.1 ± 0.87 35.0 ± 2.2 
Temporal lobe 9.6 ± 0.85 34.0 ± 3.7 
Occipital lobe 9.3 ± 0.89 40.4 ± 3.7 
Cingulate gyrus 8.9 ± 0.88 32.5 ± 4.1 
Hippocampus n.a. ± n.a. 47.9 ± 11.4 
Insula n.a. ± n.a. 30.1 ± 5.8 
Striatum 8.7 ± 0.94 40.7 ± 6.6 
Globus pallidus n.a. ± n.a. 21.4 ± 3.8 
Basal forebrain n.a. ± n.a. 41.3 ± 5.6 
Claustrum n.a. ± n.a. 53.9 ± 14.4 
Amygdala n.a. ± n.a. 54.6 ± 9.1 
Thalamus 5.5 ± 0.57 55.5 ± 10.9 
Cerebellum 5.5 ± 0.57 15.1 ± 3.9 
Brainstem 6.7 ± 0.67 46.2 ± 4.6 
 
Distribution volume estimates (𝑉𝑇) refer to a population of 11 healthy subjects (Lohith et al., 2014). Genomic data 
(mRNA) are derived from the Allen human brain atlas (query: OPRL1). For each region the average values and the 
standard deviations across subjects are reported. 
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Supplementary Table 6 – [11C](R)rolipram data 
ROIs 
𝑽𝑻 
(ml/cm3) 
mRNA 
(unitless) 
Frontal lobe 0.53 ± 0.13 71.7 ± 75.6 
Parietal lobe 0.56 ± 0.14 42.1 ± 7.7 
Temporal lobe 0.56 ± 0.13 41.7 ± 5.0 
Occipital lobe 0.45 ± 0.13 45.2 ± 9.5 
Cingulate gyrus 0.57 ± 0.14 38.5 ± 6.4 
Hippocampus 0.55 ± 0.15 n.a. ± n.a. 
Insula 0.63 ± 0.15 37.1 ± 5.1 
Striatum 0.63 ± 0.16 57.5 ± 10.2 
Globus pallidus 0.57 ± 0.13 94.1 ± 23.2 
Basal forebrain 0.59 ± 0.17 60.0 ± 16.5 
Claustrum n.a. ± n.a. 54.5 ± 15.2 
Amygdala 0.56 ± 0.14 48.7 ± 16.0 
Thalamus 0.57 ± 0.14 54.3 ± 12.9 
Cerebellum 0.45 ± 0.11 24.2 ± 7.8 
Brainstem 0.38 ± 0.08 n.a. ± n.a. 
 
Distribution volume estimates (𝑉𝑇) refer to a population of 12 healthy subjects (Zanotti-Fregonara et al., 2011). 
Genomic data (mRNA) are derived from the Allen human brain atlas (query: PDE4). For each region the average 
values and the standard deviations across subjects are reported. 
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Supplementary Table 7 – [11C]Raclopride 
ROIs 
𝑩𝑷𝑵𝑫 
(untiless) 
mRNA 
(unitless) 
Frontal lobe 0.26 ± 0.03 4.7 ± 0.6 
Parietal lobe 0.23 ± 0.02 5.0 ± 0.5 
Temporal lobe 0.27 ± 0.02 5.5 ± 0.6 
Occipital lobe 0.23 ± 0.02 5.6 ± 1.0 
Cingulate gyrus 0.26 ± 0.03 6.0 ± 2.4 
Hippocampus 0.21 ± 0.05 9.2 ± 4.6 
Insula 0.34 ± 0.06 5.3 ± 1.0 
Striatum 1.60 ± 0.30 41.3 ± 9.2 
Globus pallidus n.a. ± n.a. n.a. ± n.a. 
Basal forebrain 0.72 ± 0.13 12.4 ± 2.3 
Claustrum n.a. ± n.a. 11.3 ± 3.1 
Amygdala n.a. ± n.a. 9.5 ± 2.1 
Thalamus 0.37 ± 0.07 13.7 ± 2.6 
Cerebellum Reference region – discarded from the analysis 
Brainstem n.a. ± n.a. 15.3 ± 2.5. 
 
Binding potential (𝐵𝑃𝑁𝐷) refer to a population of 10 healthy subjects (Pavese et al., 2006). Genomic data (mRNA) are 
derived from the Allen human brain atlas (query: DRD2). For each region the average values and the standard 
deviations across subjects are reported. 
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Supplementary Figure 1 – Single subject analysis with [11C]WAY100635 PET data 
Panels A-C show some representative single-subject genomic plot applications. Both VT (x-axis) and mRNA (y-axis) 
standard errors are reported. Red lines refer to genomic plot regressions. Black dashed lines refer to the data 
regression with x-intercepts forced to the population  VND reference value. Panel D shows the distribution of VND 
estimates obtained with the single subject analysis. Population VND reference estimate (red line) and its standard 
deviation (grey area) are compared with single subject VND estimates (blue circles). Population average of VND 
individual estimates (dashed black line) is also reported.  
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Supplementary Figure 2 – Single subject analysis with [11C]Raclopride PET data 
Panels A-C show some representative single-subject genomic plot applications. Both 𝐵𝑃𝑁𝐷 (x-axis) and mRNA (y-
axis) standard errors are reported. Red lines refer to genomic plot regressions. Black dashed lines refer to the data 
regression with x-intercepts forced to the origin. Panel D shows the VND absolute biases, defined as the relative 
difference between the individual genomic plot estimates and the single-subject reference values (as defined by the 
reference region). 
 
